MARKET

FSTX

FSTX

F-Star Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.30
+0.04
+0.56%
After Hours: 6.27 -0.03 -0.40% 19:10 07/01 EDT
OPEN
6.26
PREV CLOSE
6.26
HIGH
6.34
LOW
6.24
VOLUME
272.19K
TURNOVER
0
52 WEEK HIGH
8.60
52 WEEK LOW
2.070
MARKET CAP
135.71M
P/E (TTM)
-5.2984
1D
5D
1M
3M
1Y
5Y
How Much Of F-star Therapeutics, Inc. (NASDAQ:FSTX) Do Institutions Own?
If you want to know who really controls F-star Therapeutics, Inc. ( NASDAQ:FSTX ), then you'll have to look at the...
Simply Wall St. · 06/24 12:06
BUZZ-China's Sino Biopharma posts best session in 3 months on unit's F-star buyout deal
reuters.com · 06/24 06:16
--SVB Securities Downgrades F-star Therapeutics to Market Perform From Outperform; Price Target is $7
MT Newswires · 06/24 05:00
Nasdaq Jumps Over 100 Points; Applied Therapeutics Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Thursday.
Benzinga · 06/23 19:13
Dow Jones Turns Lower; F-star Therapeutics Shares Spike Higher
U.S. stocks pared gains midway through trading, with the Dow Jones dropping 100 points on Thursday.
Benzinga · 06/23 16:31
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
 Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.
Benzinga · 06/23 16:29
--Ladenburg Thalmann Downgrades F-star Therapeutics to Neutral From Buy
MT Newswires · 06/23 15:11
--Laidlaw Downgrades F-star Therapeutics to Hold From Buy
MT Newswires · 06/23 15:10
More
No Data
Learn about the latest financial forecast of FSTX. Analyze the recent business situations of F-Star Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
16.67%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average FSTX stock price target is 26.75 with a high estimate of 35.00 and a low estimate of 7.00.
High35.00
Average26.75
Low7.00
Current 6.27
EPS
Actual
Estimate
-0.62-0.31-0.010.30
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 70
Institutional Holdings: 12.23M
% Owned: 56.72%
Shares Outstanding: 21.56M
TypeInstitutionsShares
Increased
9
443.95K
New
7
204.02K
Decreased
11
541.89K
Sold Out
9
695.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.77%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Nessan Bermingham
President/Chief Executive Officer/Director
Eliot Forster
Chief Financial Officer/Treasurer/Secretary
Darlene Deptula-Hicks
Chief Scientific Officer
Neil Brewis
Other
Louis Kayitalire
Independent Director
David Arkowitz
Independent Director
Edward Benz
Independent Director
Todd Brady
Independent Director
Pamela Klein
Independent Director
Geoffrey Race
No Data
No Data
About FSTX
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing next-generation immunotherapies to transform the lives of patients with cancer. The Company's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.

Webull offers kinds of F-Star Therapeutics Inc stock information, including NASDAQ:FSTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FSTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FSTX stock methods without spending real money on the virtual paper trading platform.